The Trump administration's reorganization of HHS, combined with significant reductions in workforce, could jeopardize research across the entire spectrum of cancer care, according to a statement from the American Cancer Society (ACS).
In another statement on HHS restructuring, the American Society of Hematology expressed it was "gravely" concerned about "sweeping changes" and urged thoughtful reform that prioritizes patient access, innovative research, and hematology progress.
The ACS also lauded bipartisan legislation introduced in the House to extend funding to expand access to screening programs in breast and cervical cancer.
A personalized app that tracks user circadian rhythms to formulate recommendations for managing cancer-related fatigue is in the works. (Michigan Medicine, Cell Reports Medicine)
The FDA expanded indications for lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to include metastatic castration-resistant prostate cancer previously treated with an androgen receptor inhibitor and considered appropriate to delay taxane therapy.
The agency also expanded indications for cabozantinib (Cabometyx) to include patients 12 or older with certain previously treated pancreatic and extra-pancreatic neuroendocrine tumors.
The imminent departure of two top cancer regulators at the FDA has created uncertainty and raised concerns about the potential impact on the drug review process. (STAT)
King Charles III canceled a series of scheduled events as a result of a brief hospitalization to manage side effects from treatment of a still-undisclosed form of cancer. (People)
Daily physical activity, even light-intensity activities, may reduce the risk of developing cancer. (NIH, British Journal of Sports Medicine)
Equillium announced that the monoclonal antibody itolizumab failed to improve response rate versus standard of care for acute graft-versus-host disease.
The American Society of Clinical Oncology updated its guidance for fertility preservation in people with cancer.
A primer on kinases, which have figured prominently in recent breakthroughs in cancer and other diseases. (Labiotech)
A group of patients whose breast cancers were treated without surgery remain recurrence-free after 5 years of follow-up. (University of Texas MD Anderson Cancer Center, JAMA Oncology)
Delaying surgery for more than 6 weeks after diagnosis may increase the risk of death for women with hormone receptor-positive, HER2-negative breast cancer. (University of Oklahoma, Breast Cancer Research)
Digital polymerase chain reaction accurately identified chronic myeloid leukemia in deep molecular remission, which might allow some patients to discontinue drug treatment. (Journal of Molecular Diagnostics)
author['full_name']
Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow